ClinicalTrials.Veeva
Menu

Find clinical trials for Multiple Myeloma in Hanyang, Seoul

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Plasma Cell Cancer
Recurrence
Cancer
Hematologic Cancer
Non-Hodgkin Lymphoma
Lymphoma
Leukemia

Multiple Myeloma trials near Hanyang, Seoul, KOR:

Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma (DREAMM 9)

phase 3 dose (RP3D) in adult participants with newly diagnosed multiple myeloma (NDMM). Participants will receive the combination o...

Active, not recruiting
Multiple Myeloma
Drug: Dexamethasone
Drug: Belantamab mafodotin

Phase 1

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Seoul, South Korea and 29 other locations

Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant (MagnetisMM-7)

monotherapy (control) in participants with newly diagnosed multiple myeloma after undergoing autologous stem cell transplant. In Pa...

Active, not recruiting
Multiple Myeloma
Drug: Lenalidomide
Drug: Elranatamab

Phase 3

Pfizer
Pfizer

Seoul, Seoul-teukbyeolsi [seoul], South Korea and 211 other locations

A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments (DynaMMic-1)

doses of single agent belantamab in participants with refractory multiple myeloma (RRMM) who have received at least 3 prior therapi...

Enrolling
Multiple Myeloma
Drug: Pomalidomide
Drug: Dexamethasone

Phase 1, Phase 2

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Seoul, South Korea and 43 other locations

A Study of Belantamab Mafodotin Monotherapy in Multiple Myeloma Participants With Normal and Varying Degree of Impaired Renal Function (DREAMM12)

antibody (mAb). Renal impairment is a major complication of multiple myeloma (MM) and the majority of MM participants is either at ...

Active, not recruiting
Multiple Myeloma
Drug: Belantamab mafodotin

Phase 1

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Seoul, South Korea and 3 other locations

Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma (DREAMM 8)

(Arm A) compared with that of combination of pomalidomide, bortezomib and dexamethasone (Arm B) in participants with relapsed/refractory multiple...

Active, not recruiting
Multiple Myeloma
Drug: Dexamethasone
Drug: Bortezomib

Phase 3

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Seoul, South Korea and 121 other locations

Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM-3)

This open-label, randomized study for evaluating the efficacy and safety of single agent belantamab mafodotin when compared to pom/dex in participant...

Active, not recruiting
Multiple Myeloma
Drug: Belantamab mafodotin
Drug: Pom/dex (Pomalidomide plus low dose Dexamethasone)

Phase 3

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Seoul, South Korea and 135 other locations

Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 5)

B-cell maturation antigen (BCMA) is a target present on tumor cells in participants with multiple myeloma. Belantamab mafodotin (GS...

Active, not recruiting
Multiple Myeloma
Drug: GSK3174998
Drug: Pomalidomide

Phase 1, Phase 2

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Seoul, South Korea and 37 other locations

Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (EXCALIBER-RRMM)

with dexamethasone and daratumumab (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in participants with relapsed or refractory multiple...

Active, not recruiting
Multiple Myeloma
Drug: Bortezomib
Drug: Dexamethasone

Phase 3

Celgene
Celgene

Seoul, South Korea and 265 other locations

Locations recently updated

A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)

This study is for adults with multiple myeloma (a type of blood cancer) that has come back after being treated earlier or isn't res...

Enrolling
Multiple Myeloma
Drug: Belantamab mafodotin
Drug: Dexamethasone

Phase 2

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Seoul, South Korea and 58 other locations

Status recently updated

Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma (CERVINO)

Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spon...

Enrolling
Active, not recruiting
Multiple Myeloma
Drug: Carfilzomib
Drug: Etentamig

Phase 3

AbbVie
AbbVie

Seoul, Seoul Teugbyeolsi, South Korea and 165 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2026 Veeva Systems